We refer to our letter dated June 18 2022 wherein we informed that the Board of Directors of the Company at its meeting held on June 17 2022 has approved the acquisition of 51% equity shares in GLS Pharma Limited operating in oncology business and having manufacturing facility in Hyderabad for a total consideration of Rs. 28.05 crores.In this regard we inform you that the Company has completed the aforesaid acquisition of 51% of equity share capital of GLS Pharma Limited on August 17 2022 and it has now become the subsidiary of the Company.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
